PACIRA BIOSCIENCES, INC.

NASDAQ: PCRX (Pacira BioSciences, Inc.)

Kemas kini terakhir: 4 hari lalu, 6:20PM

24.19

0.12 (0.50%)

Penutupan Terdahulu 24.07
Buka 24.74
Jumlah Dagangan 552,877
Purata Dagangan (3B) 634,377
Modal Pasaran 1,086,922,496
Harga / Pendapatan (P/E TTM) 51.47
Harga / Pendapatan (P/E Ke hadapan) 7.36
Harga / Jualan (P/S) 1.53
Harga / Buku (P/B) 1.42
Julat 52 Minggu
16.64 (-31%) — 27.64 (14%)
Tarikh Pendapatan 6 Nov 2025
Margin Keuntungan -14.76%
Margin Operasi (TTM) 4.63%
EPS Cair (TTM) -2.24
Pertumbuhan Hasil Suku Tahunan (YOY) 1.10%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -46.40%
Jumlah Hutang/Ekuiti (D/E MRQ) 79.70%
Nisbah Semasa (MRQ) 2.41
Aliran Tunai Operasi (OCF TTM) 175.75 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 144.75 M
Pulangan Atas Aset (ROA TTM) 3.56%
Pulangan Atas Ekuiti (ROE TTM) -12.27%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menaik Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menaik Bercampur
Stok Pacira BioSciences, Inc. Menurun Menaik

AISkor Stockmoo

1.0
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal 4.0
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
PCRX 1 B - 51.47 1.42
RGC 6 B - - 1.22
ANIP 2 B - 53.03 3.63
COLL 2 B - 29.36 5.51
AMPH 1 B - 12.26 1.58
DVAX 1 B - - 2.41

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 1.79%
% Dimiliki oleh Institusi 110.89%
Julat 52 Minggu
16.64 (-31%) — 27.64 (14%)
Julat Harga Sasaran
28.00 (15%) — 38.00 (57%)
Tinggi 38.00 (HC Wainwright & Co., 57.09%) Beli
Median 33.00 (36.42%)
Rendah 28.00 (Truist Securities, 15.75%) Beli
Purata 33.00 (36.42%)
Jumlah 2 Beli
Harga Purata @ Panggilan 22.97
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 17 Nov 2025 38.00 (57.09%) Beli 23.88
Truist Securities 07 Nov 2025 28.00 (15.75%) Beli 22.05

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
03 Dec 2025 Pengumuman Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2025 Pengumuman Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
26 Nov 2025 Pengumuman Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
11 Nov 2025 Pengumuman Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
10 Nov 2025 Pengumuman DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
06 Nov 2025 Pengumuman Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
05 Nov 2025 Pengumuman Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
04 Nov 2025 Pengumuman Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
30 Oct 2025 Pengumuman Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
28 Oct 2025 Pengumuman Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
27 Oct 2025 Pengumuman Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
23 Oct 2025 Pengumuman Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
21 Oct 2025 Pengumuman Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
20 Oct 2025 Pengumuman Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
03 Oct 2025 Pengumuman Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda